Compare TOL & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | MEDP |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 11.7B |
| IPO Year | 1994 | 2016 |
| Metric | TOL | MEDP |
|---|---|---|
| Price | $139.43 | $416.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | $164.44 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 840.6K | 455.2K |
| Earning Date | 05-19-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 2.19 | ★ 4.28 |
| Revenue | ★ $7,143,258,000.00 | N/A |
| Revenue This Year | N/A | $13.19 |
| Revenue Next Year | $6.01 | $7.75 |
| P/E Ratio | ★ $64.89 | $98.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $100.92 | $284.10 |
| 52 Week High | $168.36 | $628.92 |
| Indicator | TOL | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 36.57 |
| Support Level | $133.98 | $382.68 |
| Resistance Level | $139.64 | $485.13 |
| Average True Range (ATR) | 3.86 | 17.47 |
| MACD | -0.35 | -10.02 |
| Stochastic Oscillator | 5.37 | 27.75 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.